Straits Times Index
3,204.82 +2.01 (+0.06%) Nikkei
32,402.41 -168.62 (-0.52%) Hang Seng
18,057.45 +402.04 (+2.28%) FTSE 100
7,683.91 +5.29 (+0.07%) Bitcoin USD
26,579.03 +9.58 (+0.04%) CMC Crypto 200
565.87 -2.18 (-0.38%)
Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 75.27 |
| Open | 74.76 |
| Bid | 75.01 x 1400 |
| Ask | 75.02 x 900 |
| Day's range | 74.35 - 75.61 |
| 52-week range | 61.45 - 89.74 |
| Volume | |
| Avg. volume | 5,546,593 |
| Market cap | 93.463B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 17.24 |
| EPS (TTM) | 4.35 |
| Earnings date | 25 Oct 2023 - 30 Oct 2023 |
| Forward dividend & yield | 3.00 (3.99%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | 85.46 |
Motley Fool3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
ZacksGilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Business WireCHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
FOSTER CITY, Calif., September 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can
